Frontlight ResearchEarly access
Not yet taking people in NetherlandsPhase 1
Brain scan tracer to study the blood–brain barrier in glioblastoma
Tests a PET scan tracer of barrier function in adults suspected of glioblastoma.
Key facts
- Who runs it
- Universitair Medisch Centrum Groningen
- Where
- Groningen, NetherlandsSee the site
- Trial code
- Registry title
- [¹⁸F]MC225 PET Analysis of Blood–Brain Barrier Function in Glioblastomas
- Status
- Not yet recruiting
- Phase
- Phase 1
- People taking part
- 10 people, planned
- Started
- 2 Nov 2026
- Expected to end
- 2 May 2029
- Type of study
- Interventional
- Record updated
- 28 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who are thought, from scans, to have glioblastoma and will have surgery to reduce the tumor. It studies how the blood–brain barrier works using a PET scan.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Suspected glioblastoma on scans, mostly on one side of the brain, with surgery planned to reduce the tumor
- Earlier treatment
- Cannot be taking medicines that strongly affect P-glycoprotein function, unless they can be safely stopped before imaging
Main reasons for not taking part
- Cannot safely have PET or MRI, blood vessel catheters or gadolinium contrast
- Pregnant or breastfeeding
- Cannot give informed consent
- Brain or mental health conditions that could affect the study, in the investigator's view
- Tumor on both sides of the brain that prevents regional analysis
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Age 18 years or older
- Radiological suspicion of glioblastoma
- Candidate for tumor reductive surgery
- Predominantly unilateral tumor suitable for regional imaging analysis
- Eligible for contrast-enhanced MRI according to routine clinical safety screening
- Able to undergo PET imaging, arterial and venous blood sampling according to the study protocol
- Able to understand study information and provide written informed consent
- Imaging procedures can be performed within 14 days prior to surgery without delaying standard clinical care
Who cannot take part
- Use of medications known to significantly affect P-glycoprotein function, unless these can be safely discontinued prior to imaging
- Contraindications to study procedures, including PET and MRI imaging, arterial or venous catheterisation, MRI, or administration of gadolinium-based contrast agents (e.g., non-MRI-compatible implants, severe contrast allergy, or impaired renal function)
- Relevant neurological or psychiatric conditions that may interfere with study participation, imaging quality, or interpretation of results, at the discretion of the investigator
- Pregnancy or breastfeeding
- Inability to provide informed consent
- Extensive bilateral tumor involvement precluding regional analysis
Where in Netherlands
- UMCGGroningen, NetherlandsNot yet recruiting
About the trial
What the trial wants to find out
To quantify [¹⁸F]MC225 tracer kinetics as a measure of P-glycoprotein function at the blood–brain barrier in tumor and peritumoral regions of patients with radiological suspicion of glioblastoma.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- [¹⁸F]MC225 PET Analysis of Blood–Brain Barrier Function in Glioblastomas
- Plain-language title
- Brain scan tracer to study the blood–brain barrier in glioblastomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 28 September 2026